Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Scienmag

SEPTEMBER 18, 2020

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53

Protein Antibody In-Vitro Scientist 53

XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. They reported their findings last week in the journal Science.

Allergies 98

Allergies Antibody In-Vitro Development 98

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

Drug Discovery World

APRIL 8, 2024

Outstanding Achievement Award Pfizer Chairman and CEO Dr Albert Bourla received the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine on behalf of Pfizer during the Opening Ceremony.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

BioSpace

FEBRUARY 16, 2021

In an editorial letter in The New England Journal of Medicine, Jeff Shuren, M.D., the FDA’s device center director, and the agency’s in vitro diagnostics chief Timothy Stenzel, M.D., wrote that the agency planned to revisit their policy on antibody testing after it had authorized several s.

In-Vitro 55

In-Vitro Antibody Medicine 55

The Pharma Data

MARCH 25, 2022

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

XTalks

NOVEMBER 20, 2020

A new type of test based on detection of activated T cells may prove to have greater utility in determining whether someone has had a COVID-19 infection compared to a traditional antibody test. Meanwhile, Indoor Biotechnologies has been working with Cardiff University’s School of Medicine on its test.

Antibody 98

Antibody Immune Response Protein In-Vitro 98

The Pharma Data

MAY 27, 2022

Roche today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June. months, 39.4%

Antibody 52

Antibody In-Vitro Medicine Engineer 52

The Pharma Data

MARCH 29, 2022

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice).

Antibody 52

Antibody In-Vitro Trials Development 52

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. This designation for gantenerumab marks the 39th Breakthrough Therapy Designation for Roche’s portfolio of medicines.

Antibody 52

Antibody Medicine In-Vitro Trials 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. We are excited about the potential for one medicine to serve both as a treatment for those infected as well as protection for people exposed to the virus. and around the world.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

APRIL 7, 2021

Anti-p53 antibodies are antibodies that mistakenly target a patient’s own tissues, leading to a growth of solid tumors. today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. said Thomas Schinecker, CEO Roche Diagnostics.

In-Vitro 52

In-Vitro Antibody Genetics Protein 52

Drug Discovery World

OCTOBER 31, 2023

The free summit, sponsored by Taconic, will offer expert thought leadership on cancer research, precision medicine and immunotherapy. Raffi Tonikian DDW is delighted to confirm that the event will feature a talk by Dr Raffi Tonikian, Director of Translational Biomarkers at AbCellera, sharing his broad expertise in autoimmunity and oncology.

In-Vitro 52

In-Vitro Research Medicine Development 52

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody. TJ” Esparza, BS, and David L.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

The Pharma Data

MAY 17, 2021

The European Commission’s Medical Device Coordination Group (MDCG) sent a notice to in vitro diagnostic (IVD) makers and their authorized representatives reminding them of their obligation to assess the impact of COVID-19 variants on the performance of their tests. . Posted 17 May 2021 | By Michael Mezher .

In-Vitro 52

In-Vitro Manufacturing Vaccination Vaccine 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Previously, he held roles as CMO at Trimeris Inc.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Monoclonal antibodies (mAbs). Somatic cells. Gene and cellular therapies. Recombinant therapeutic proteins. Interferons.

Development 180

Development Protein Production Hormones 180

The Pharma Data

SEPTEMBER 1, 2020

with whom Roche has a global distribution agreement and had also launched a Rapid Antibody Test in July. Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Roche also intends to file for Emergency Use Authorisation (EUA) to the U.S.

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

The Pharma Data

AUGUST 16, 2020

First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks. First and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology.

FDA Approval 52

FDA Approval Antibody Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 23, 2021

Vital results from the phase I/ II GO29781 study, presented for the first time and featured in the ASH press programme, showing mosunetuzumab, a CD20xCD3 T- cell engaging bispecific antibody immunotherapy, achieved high response rates with a manageable safety profile. The safety profile was similar for Polivy plus R-CHP versus R-CHOP.1

Antibody 52

Antibody In-Vitro Development Genome 52

pharmaphorum

DECEMBER 15, 2022

Boehringer Ingelheim taps new head of medicine. As we reported 4th November, Boehringer Ingelheim brought on former Novartis neurosciences head Lykke Hinsch Gylvin (pictured below) into the role of head of medicine and chief medical officer. Read on for a round-up of some of the biggest moves that crossed our desks.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

XTalks

MARCH 1, 2021

In addition, the companies are also engaged in discussions with regulatory agencies, including the US Food and Drug Administration (FDA) and the European Medicines Agency, with respect to a registration-enabling study for the evaluation of a variant-specific vaccine with a new mRNA code. The new mRNA sequence would be based on the B.1.351

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. Ronapreve is a combination of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Antibody 52

Antibody Medicine Production In-Vitro 52

The Pharma Data

JANUARY 19, 2021

Ortho Clinical Diagnostics is a leader in in vitro diagnostics. On January 12, its VITROS SARS-CoV-2 Antigen Test for mass-scale COVID-19 testing received FDA Emergency Use Authorization. The year is starting off with a number of biopharma and life sciences initial public offerings (IPOs). TCR2 Therapeutics – The Cambridge, Mass.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

Drug Discovery World

FEBRUARY 16, 2024

DDW recently hosted an online event, sponsored by Taconic Biosciences, which outlined areas of advancement and opportunity in the cancer research market. Megan Thomas summarises the key points examined by the participating experts. They make the most of their environment to gain a survival advantage, and there are a lot of elements involved.

Research 52

Research In-Vitro Drugs Vaccination 52

The Pharma Data

SEPTEMBER 9, 2020

Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD. Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD. ENSPRYNG lowered relapse severity in double-blind periods of SAkura Phase III studies. ENSPRYNG was recently approved by the U.S.

Antibody 52

Antibody Medicine HR In-Vitro 52

The Pharma Data

NOVEMBER 11, 2021

”People with COVID-19 across Europe are formerly being treated with Ronapreve grounded on exigency authorisations that followed the CHMP’s scientific opinion before this time, and we ’re pleased that the commission has now recommended the blessing of the antibody combination.” It has also been conditionally recommended by WHO.

In-Vitro 40

In-Vitro Antibody Medicine Development 40

The Pharma Data

MAY 15, 2023

If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 1,2 Vabysmo’s safety profile was consistent with previous trials. Roche’s Chief Medical Officer and Head of Global Product Development. “If In BALATON, vision gains were +16.9

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

pharmaphorum

JANUARY 17, 2023

Conjugation of targeting ligands such as GalNAc, transferrin receptor antibodies, and lipophilic moieties to siRNAs and ASO have facilitated delivery to liver, muscle, and CNS tissues, respectively, in preclinical or clinical studies. In addition, the construction of a specialised manufacturing facility for mRNA vaccines was agreed.

Vaccination 89

Vaccination Vaccine In-Vivo In-Vitro 89

The Pharma Data

NOVEMBER 29, 2021

First Combination of Immunotherapy With Tyrosine Kinase Inhibitor Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation.

In-Vitro 52

In-Vitro Containment Development Medicine 52

The Pharma Data

AUGUST 6, 2020

Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified. This includes studies evaluating Tecentriq both alone and in combination with other medicines. OS follow-up is planned to continue until final analysis.

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

APRIL 23, 2021

These results were published in the New England Journal of Medicine in August 2020. Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia. The VIALE-A study showed Venclyxto plus azacitidine significantly improved overall survival compared to azacitidine alone.

Medicine 40

Medicine In-Vitro Antibody Branding 40

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. Chief Medical Officer and Head of Global Product Development.

Antibody 40

Antibody In-Vitro Development Trials 40

XTalks

DECEMBER 19, 2023

One of the key factors in its success is its versatility as it is getting approvals for different types of cancers, especially at the advanced stages where other medicines are no longer working. As we approach the end of 2023, a retrospective look at the statistics from 2022 reveals the top 20 drugs dominating retail sales.

Sales 64

Sales FDA Approval Drugs Vaccination 64

The Pharma Data

APRIL 27, 2021

The FDA’s Accelerated Approval Program allows for conditional approval of a medicine that fills an unmet medical need for a serious condition, with specific postmarketing requirements (PMRs) to confirm the clinical benefit and convert to regular approval. Roche’s Chief Medical Officer and Head of Global Product Development.

Medicine 40

Medicine In-Vitro Antibody Development 40